Your browser is no longer supported. Please, upgrade your browser.
CRMD [NASD]
CorMedix Inc.
Index- P/E- EPS (ttm)-0.73 Insider Own0.40% Shs Outstand38.11M Perf Week-9.72%
Market Cap158.09M Forward P/E- EPS next Y-1.11 Insider Trans9.40% Shs Float37.45M Perf Month-14.69%
Income-26.50M PEG- EPS next Q-0.23 Inst Own31.30% Short Float4.91% Perf Quarter-12.00%
Sales0.20M P/S790.44 EPS this Y57.20% Inst Trans0.08% Short Ratio8.74 Perf Half Y-31.25%
Book/sh1.82 P/B2.30 EPS next Y-38.80% ROA-36.60% Target Price22.00 Perf Year-50.88%
Cash/sh1.90 P/C2.20 EPS next 5Y- ROE-39.20% 52W Range3.77 - 18.80 Perf YTD-8.13%
Dividend- P/FCF- EPS past 5Y23.30% ROI-49.90% 52W High-78.38% Beta2.38
Dividend %- Quick Ratio14.00 Sales past 5Y2.60% Gross Margin16.90% 52W Low7.84% ATR0.26
Employees35 Current Ratio14.00 Sales Q/Q-59.10% Oper. Margin- RSI (14)30.59 Volatility7.03% 5.85%
OptionableYes Debt/Eq0.00 EPS Q/Q-0.80% Profit Margin- Rel Volume0.28 Prev Close4.18
ShortableYes LT Debt/Eq0.00 EarningsNov 09 AMC Payout- Avg Volume210.40K Price4.07
Recom2.00 SMA20-11.95% SMA50-16.00% SMA200-32.38% Volume41,491 Change-2.75%
Feb-17-21Initiated Needham Buy $31
Sep-29-20Initiated JMP Securities Mkt Outperform $22
Sep-21-20Initiated Truist Buy $20
Dec-18-19Initiated B. Riley FBR Buy $48
Mar-26-19Reiterated H.C. Wainwright Buy $3 → $15
Dec-06-18Initiated ROTH Capital Buy $6
Sep-25-17Reiterated H.C. Wainwright Buy $3 → $4
Aug-10-17Reiterated Rodman & Renshaw Buy $5 → $3
May-05-17Reiterated Rodman & Renshaw Buy $6 → $5
Nov-11-16Reiterated FBR & Co. Outperform $6 → $4
Mar-17-16Reiterated FBR Capital Outperform $7 → $6
Mar-03-16Initiated FBR Capital Outperform $7
Nov-16-15Reiterated ROTH Capital Neutral $2.75 → $2.50
Oct-29-15Reiterated ROTH Capital Neutral $4.50 → $2.75
May-06-15Downgrade ROTH Capital Buy → Neutral $2.50 → $7.50
Dec-08-14Reiterated ROTH Capital Buy $3 → $2.50
Oct-03-11Downgrade Maxim Group Buy → Hold
Jan-04-22 08:00AM  
Nov-09-21 04:05PM  
Nov-02-21 09:00PM  
08:30AM  
Oct-28-21 03:05PM  
Oct-20-21 08:30AM  
Oct-04-21 04:01PM  
Sep-30-21 08:00AM  
Sep-20-21 12:45PM  
11:40AM  
11:00AM  
11:00AM  
10:10AM  
09:36AM  
05:50AM  
Sep-19-21 09:15PM  
01:15PM  
10:21AM  
Sep-17-21 07:26PM  
05:04PM  
03:22PM  
01:30PM  
01:00PM  
11:30AM  
11:20AM  
10:00AM  
10:00AM  
09:45AM  
09:05AM  
07:55AM  
Sep-16-21 08:45PM  
04:05PM  
03:10PM  
01:15PM  
08:37AM  
Sep-15-21 08:45PM  
05:25PM  
04:35PM  
12:10PM  
11:00AM  
10:30AM  
10:30AM  
09:30AM  
Sep-14-21 06:30PM  
04:48PM  
01:50PM  
12:10PM  
12:00PM  
11:00AM  
10:25AM  
10:00AM  
09:00AM  
08:15AM  
05:40AM  
Sep-13-21 11:26PM  
09:10PM  
07:30PM  
03:50PM  
03:08PM  
01:15PM  
11:50AM  
11:50AM  
11:35AM  
11:35AM  
11:00AM  
10:45AM  
10:19AM  
Sep-10-21 08:10PM  
07:39PM  
01:40PM  
01:00PM  
12:25PM  
11:59AM  
10:00AM  
Sep-09-21 06:30PM  
06:03PM  
03:00PM  
02:15PM  
01:00PM  
10:45AM  
10:00AM  
05:50AM  
Sep-08-21 09:13PM  
01:00PM  
12:00PM  
Sep-07-21 09:35PM  
08:59PM  
08:45PM  
02:16PM  
01:32PM  
12:00PM  
09:42AM  
08:30AM  
Sep-04-21 06:30PM  
Sep-03-21 12:29PM  
11:00AM  
Sep-02-21 08:45PM  
07:44PM  
06:45PM  
06:06PM  
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. It primarily focuses on the development of its lead product candidate DefenCath/Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
David Matthew TInterim CEO and CFODec 06Buy4.501,0004,5003,150Dec 07 06:44 PM
David Matthew TInterim CEO and CFODec 06Buy4.501,0004,5003,150Dec 07 06:44 PM
David Matthew TInterim CEO and CFONov 17Buy5.071,0005,0702,150Nov 19 09:53 AM
Kaplan MyronDirectorNov 16Buy5.1410,00051,400175,034Nov 19 04:45 PM
Masson-Hurlburt ElizabethEVP, Head of Clinical OpsMay 21Sale6.928,00055,3940May 25 04:46 PM
Kaplan MyronDirectorMay 17Buy6.0315,00090,477165,034May 19 05:40 PM